{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:03Z","timestamp":1790660703447,"version":"4.1.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be complicated by vascular events, including both thrombosis and bleeding. This disorder may also transform into more aggressive myeloid neoplasms, in particular into myelofibrosis. The identification of somatic mutations of JAK2, CALR, or MPL, found in about 90% of patients, has considerably improved the diagnostic approach to this disorder. Genomic profiling also holds the potential to improve prognostication and, more generally, clinical decision-making because the different driver mutations are associated with distinct clinical features. Prevention of vascular events has been so far the main objective of therapy, and continues to be extremely important in the management of patients with ET. Low-dose aspirin and cytoreductive drugs can be administered to this purpose, with cytoreductive treatment being primarily given to patients at high risk of vascular complications. Currently used cytoreductive drugs include hydroxyurea, mainly used in older patients, and interferon \u03b1, primarily given to younger patients. There is a need for disease-modifying drugs that can eradicate clonal hematopoiesis and\/or prevent progression to more aggressive myeloid neoplasms, especially in younger patients. In this article, we use a case-based discussion format to illustrate our approach to diagnosis and treatment of ET.<\/jats:p>","DOI":"10.1182\/blood-2016-05-643346","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T22:20:13Z","timestamp":1472163613000},"page":"2403-2414","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":71,"title":["How I treat essential thrombocythemia"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-9504","authenticated-orcid":false,"given":"Elisa","family":"Rumi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy; and"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-8817","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy; and"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111906322590300_B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"20","key":"2019111906322590300_B2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111906322590300_B3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2019111906322590300_B4","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2019111906322590300_B5","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111906322590300_B6","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2019111906322590300_B8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111906322590300_B9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111906322590300_B10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B11","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111906322590300_B12","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2019111906322590300_B13","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood-2014-06-580183","article-title":"X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations","volume":"124","author":"Allen","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2019111906322590300_B14","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111906322590300_B15","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2019111906322590300_B16","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood-2016-01-694182","article-title":"Mutant calreticulin: when a chaperone becomes intrusive","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111906322590300_B21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra035363","article-title":"Thrombocytosis","volume":"350","author":"Schafer","year":"2004","journal-title":"N Engl J Med"},{"issue":"33","key":"2019111906322590300_B22","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590]","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111906322590300_B23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111906322590300_B24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111906322590300_B25","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111906322590300_B26","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111906322590300_B27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111906322590300_B28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1413718","article-title":"A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm","volume":"372","author":"Cabagnols","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111906322590300_B29","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2014-12-616847","article-title":"CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation","volume":"125","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111906322590300_B30","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-03-632893","article-title":"Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1","volume":"125","author":"Loghavi","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111906322590300_B31","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111906322590300_B32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2141.2007.06741.x","article-title":"Amendment to the guideline for diagnosis and investigation of polycythaemia\/erythrocytosis","volume":"138","author":"McMullin","year":"2007","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111906322590300_B33","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"35","key":"2019111906322590300_B34","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111906322590300_B35","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"2","key":"2019111906322590300_B37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2019111906322590300_B38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111906322590300_B39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2019111906322590300_B40","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"2019111906322590300_B41","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"2019111906322590300_B42","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"15","key":"2019111906322590300_B43","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111906322590300_B44","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk thrombocythaemia: results from a prospective study","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"issue":"17","key":"2019111906322590300_B45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111906322590300_B46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111906322590300_B47","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111906322590300_B48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111906322590300_B49","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111906322590300_B50","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019111906322590300_B51","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111906322590300_B52","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am J Hematol"},{"issue":"32","key":"2019111906322590300_B53","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111906322590300_B54","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111906322590300_B55","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111906322590300_B56","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2019111906322590300_B57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"issue":"18","key":"2019111906322590300_B58","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111906322590300_B59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111906322590300_B60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111906322590300_B61","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2012.083097","article-title":"Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study","volume":"99","author":"Gugliotta","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2019111906322590300_B62","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111906322590300_B63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat Genet"},{"issue":"4","key":"2019111906322590300_B64","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V94.4.1480","article-title":"A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA","volume":"94","author":"Ghilardi","year":"1999","journal-title":"Blood"},{"issue":"11","key":"2019111906322590300_B65","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111906322590300_B67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A novel germline JAK2 mutation in familial myeloproliferative neoplasms","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111906322590300_B68","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111906322590300_B69","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111906322590300_B70","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.22240","article-title":"JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders","volume":"107","author":"Rumi","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111906322590300_B71","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellann\u00e9-Chantelot","year":"2006","journal-title":"Blood"},{"issue":"23","key":"2019111906322590300_B72","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/blood-2015-04-639039","article-title":"Survival in patients with familial and sporadic myeloproliferative neoplasms","volume":"125","author":"Hultcrantz","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111906322590300_B73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.2005.05400.x","article-title":"Pregnancy and its management in the Philadelphia negative myeloproliferative diseases","volume":"129","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111906322590300_B74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B75","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111906322590300_B76","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111906322590300_B77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1538-7836.2009.03686.x","article-title":"Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies","volume":"8","author":"Passamonti","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111906322590300_B78","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jch.12541","article-title":"Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis","volume":"17","author":"Xu","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"2019111906322590300_B79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.23635","article-title":"Pregnancy complications predict thrombotic events in young women with essential thrombocythemia","volume":"89","author":"Randi","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111906322590300_B80","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111906322590300_B81","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111906322590300_B82","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.13235","article-title":"Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis","volume":"169","author":"Roques","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111906322590300_B83","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists [published online ahead of print May 13, 2016]","author":"De Stefano","journal-title":"Leukemia"},{"issue":"21","key":"2019111906322590300_B84","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1847.1847","article-title":"Long-term results from a phase II open-label study of ruxolitinib in patients with essential thrombocythemia refractory to or intolerant of hydroxyurea [abstract]","volume":"124","author":"Verstovsek","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111906322590300_B85","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111906322590300_B86","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111906322590300_B87","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMe1508740","article-title":"Treating myeloproliferation\u2013on target or off?","volume":"373","author":"Armanios","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111906322590300_B88","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/20\/2403\/1397072\/blood643346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/20\/2403\/1397072\/blood643346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T06:34:31Z","timestamp":1574145271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/20\/2403\/35610\/How-I-treat-essential-thrombocythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":88,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016,11,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-05-643346","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}